Gary R. Maharaj
Also at Surmodics Inc
About
Gary R. Maharaj has been the driving force behind Surmodics, Inc. since December 2010, when he joined the company as President and Chief Executive Officer and was simultaneously appointed to its Board of Directors. His leadership has steered the company towards innovative medical device solutions, specifically focusing on proprietary surface modification and drug-delivery coating technologies that improve the detection and treatment of disease.
Prior to his tenure at Surmodics, he held significant leadership roles in the medical device industry. He served as President and CEO of Arizant Inc. from 2006 to 2010, and before that, he held senior-level management roles at Augustine Medical, Inc. as well as various management and research positions at Smith & Nephew, PLC. With over 35 years of experience in the field, his extensive background spans marketing, research and development, and executive leadership.
While specific details regarding his personal background and education are not available, his professional journey highlights a well-established commitment to innovation and excellence in the medical device sector. His career progression and focus on addressing unmet clinical needs underscore a deep expertise and passion that continues to drive advancements at Surmodics.
$SRDX Performance Under Gary R. Maharaj
Past Roles
Fixed Compensation
Performance Compensation
Non-Equity Incentive Plan Compensation
Strategic Objectives (Weight: 40% )
- Achievement details: Preside hydrophilic coating studies: 150% , Pounce venous thrombectomy system: 100% , Pounce LP arterial thrombectomy system: 150% , Sublime microcatheter launch: 100%
- Overall Strategic Achievement: 125%
Overall Weighting: Corporate Financial Objective: 60% , Strategic Objectives: 40%
Payout Details
Evaluation & Vesting:
- Evaluation Period: Fiscal Year 2024
- Vesting: Immediate payout upon determination of performance results
Target Incentive Opportunity (Part of the Performance Compensation Framework)
*Note: The performance compensation is calculated based on both corporate financial and strategic objectives with detailed achievement percentages and a target payout mechanism that results in an overall actual payout of $654,215 for fiscal year 2024. *